Premium
Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective
Author(s) -
Kron Florian,
Kutsch Nadine,
Kostenko Anna,
Dohle Ines,
Glossmann JanPeter,
Müller Dirk,
Heimann Sebastian M.,
Bahlo Jasmin,
BergweltBaildon Michael,
Eichhorst Barbara,
Wolf Jürgen,
Hallek Michael,
Zander Thomas
Publication year - 2017
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12817
Subject(s) - reimbursement , medicine , chronic lymphocytic leukemia , revenue , diagnosis related group , cost analysis , payment , emergency medicine , intensive care medicine , leukemia , finance , health care , business , engineering , economics , economic growth , reliability engineering
Objectives Treatment of chronic lymphocytic leukemia ( CLL ) is currently undergoing dramatic changes. We analyzed economic risks in hospitalized patients with CLL from a management perspective. Methods One hundred and twelve patients with CLL hospitalized in 2013 and 2014 at the University Hospital of Cologne were analyzed. To assess profit margins ( PM s) per case, diagnosis‐related group ( DRG ) reimbursement data were merged with an internal cost accounting scheme depending on age, prognostic factors, and DRG key performance indicators. Results In 112 patients, 284 cases coded by 19 different DRG with strongly fluctuating cost revenue ratios were found with an overall negative PM of €137 147. The DRG R61H was identified as the one most commonly coded (174 cases, 61.3%) with a deficit per case of €814. Subanalysis demonstrated that the payments were not cost covering due to excessive length of stay and staff costs. Significant differences in PM per case concerning age, length of stay and number of operation and procedure key ( OPS ) codes ( P < 0.05) were found. Conclusion In our research‐driven tertiary care hospital, inpatient treatment of patients with CLL is not cost covering. This analysis demonstrates the need for novel care/reimbursement structures in CLL . From a hospital management perspective, cost revenue controlling is crucial to avoid major economic risks.